HC Wainwright Reiterates Buy Rating for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $11.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 48.45% from the company’s current price.

Kamada Trading Up 1.2 %

NASDAQ KMDA opened at $7.41 on Friday. Kamada has a 12-month low of $4.74 and a 12-month high of $8.00. The company has a fifty day simple moving average of $6.08 and a two-hundred day simple moving average of $5.69. The stock has a market cap of $425.93 million, a P/E ratio of 26.46 and a beta of 0.98.

Institutional Trading of Kamada

A hedge fund recently bought a new stake in Kamada stock. Plato Investment Management Ltd bought a new position in shares of Kamada Ltd. (NASDAQ:KMDA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.